US 11,291,687

Application 17/480,534 · Granted Apr 5, 2022

Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

Estimated expiration

January 5, 2038

11y 47d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Jan 5, 2018
+ 20 years
Jan 5, 2038
PTA +0d
Jan 5, 2038
TD cap (US 10,420,799)
Jan 5, 2038
Final
Jan 5, 2038

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
September 21, 2021
Earliest effective filing
January 5, 2018
Issue date
April 5, 2022
PTA
0 days
Base expiry (before PTA)
January 5, 2038

January 5, 2018 + 20 years = January 5, 2038

  • Continuation of application 17/383,280, filed Jul 22, 2021, issued as US 11,304,979
  • Continuation of application 17/326,088, filed May 20, 2021, issued as US 11,202,803
  • Continuation of application 17/147,073, filed Jan 12, 2021, issued as US 11,013,770
  • Divisional of application 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
  • Divisional of application 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
  • Continuation of application 17/147,073, filed Jan 12, 2021, issued as US 11,013,770
  • Divisional of application 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
  • Continuation of application 17/326,088, filed May 20, 2021, issued as US 11,202,803
  • Continuation of application 17/147,073, filed Jan 12, 2021, issued as US 11,013,770
  • Divisional of application 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
  • PRO62/478,506 — Provisional — not used for base term
  • PRO62/539,410 — Provisional — not used for base term
  • PRO62/548,306 — Provisional — not used for base term
  • PRO62/554,538 — Provisional — not used for base term
  • PRO62/559,374 — Provisional — not used for base term
  • PRO62/567,121 — Provisional — not used for base term
  • PRO62/577,655 — Provisional — not used for base term
  • PRO62/582,874 — Provisional — not used for base term
  • PRO62/596,374 — Provisional — not used for base term
  • PRO62/478,506 — Provisional — not used for base term
  • PRO62/539,410 — Provisional — not used for base term
  • PRO62/548,306 — Provisional — not used for base term
  • PRO62/554,538 — Provisional — not used for base term
  • PRO62/559,374 — Provisional — not used for base term
  • PRO62/567,121 — Provisional — not used for base term
  • PRO62/577,655 — Provisional — not used for base term
  • PRO62/582,874 — Provisional — not used for base term
  • PRO62/596,374 — Provisional — not used for base term
  • PRO62/478,506 — Provisional — not used for base term
  • PRO62/539,410 — Provisional — not used for base term
  • PRO62/548,306 — Provisional — not used for base term
  • PRO62/554,538 — Provisional — not used for base term
  • PRO62/559,374 — Provisional — not used for base term
  • PRO62/567,121 — Provisional — not used for base term
  • PRO62/577,655 — Provisional — not used for base term
  • PRO62/582,874 — Provisional — not used for base term
  • PRO62/596,374 — Provisional — not used for base term
  • PRO62/478,506 — Provisional — not used for base term
  • PRO62/539,410 — Provisional — not used for base term
  • PRO62/548,306 — Provisional — not used for base term
  • PRO62/554,538 — Provisional — not used for base term
  • PRO62/559,374 — Provisional — not used for base term
  • PRO62/567,121 — Provisional — not used for base term
  • PRO62/577,655 — Provisional — not used for base term
  • PRO62/582,874 — Provisional — not used for base term
  • PRO62/596,374 — Provisional — not used for base term
  • PRO62/478,506 — Provisional — not used for base term
  • PRO62/539,410 — Provisional — not used for base term
  • PRO62/548,306 — Provisional — not used for base term
  • PRO62/554,538 — Provisional — not used for base term
  • PRO62/559,374 — Provisional — not used for base term
  • PRO62/567,121 — Provisional — not used for base term
  • PRO62/577,655 — Provisional — not used for base term
  • PRO62/582,874 — Provisional — not used for base term
  • PRO62/596,374 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 9 filed

TD caps expiration to January 5, 2038 (earliest expiring referenced patent: US 10,420,799)

  • US 10,420,799· Application 16/136,157Capping patent

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Filing date
    Sep 19, 2018
    Earliest effective filing
    Jan 5, 2018
    Issue date
    Sep 24, 2019
    PTA
    0 days
    Calculated expiration
    Jan 5, 2038

    Continuation of 15/874,718, filed Jan 18, 2018, issued as US 10,166,257

    Continuation of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063

    Continuation of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063

    Jan 5, 2018 + 20y = Jan 5, 2038

  • US 11,291,687· Application 17/480,534(from application 17/480,534)

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Filing date
    Sep 21, 2021
    Earliest effective filing
    Jan 5, 2018
    Issue date
    Apr 5, 2022
    PTA
    0 days
    Calculated expiration
    Jan 5, 2038

    Continuation of 17/383,280, filed Jul 22, 2021, issued as US 11,304,979

    Continuation of 17/326,088, filed May 20, 2021, issued as US 11,202,803

    Continuation of 17/147,073, filed Jan 12, 2021, issued as US 11,013,770

    Divisional of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063

    Divisional of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063

    Continuation of 17/147,073, filed Jan 12, 2021, issued as US 11,013,770

    Divisional of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063

    Continuation of 17/326,088, filed May 20, 2021, issued as US 11,202,803

    Continuation of 17/147,073, filed Jan 12, 2021, issued as US 11,013,770

    Divisional of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063

    Jan 5, 2018 + 20y = Jan 5, 2038

  • US 10,653,723· Application 16/746,416

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Filing date
    Jan 17, 2020
    Earliest effective filing
    Jan 5, 2018
    Issue date
    May 19, 2020
    PTA
    0 days
    Calculated expiration
    Jan 5, 2038

    Continuation of 16/192,707, filed Nov 15, 2018, issued as US 10,537,595

    Divisional of 15/874,718, filed Jan 18, 2018, issued as US 10,166,257

    Continuation of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063

    Continuation of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063

    Continuation of 15/874,718, filed Jan 18, 2018, issued as US 10,166,257

    Continuation of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063

    Jan 5, 2018 + 20y = Jan 5, 2038

  • US 11,007,226· Application 17/127,790

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Filing date
    Dec 18, 2020
    Earliest effective filing
    Jan 5, 2018
    Issue date
    May 18, 2021
    PTA
    0 days
    Calculated expiration
    Jan 5, 2038

    Divisional of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063

    Jan 5, 2018 + 20y = Jan 5, 2038

Notes (1)

  • [TD_DOCS_TRUNCATED] Found 9 filed TD documents; parsing first 3 only

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 17/480,534 · US 11,291,687

PatentReply compiles the prosecution history behind US 11,291,687: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US11291687

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.